IV Sildenafil Persistent Pulmonary Hypertension Of The Newborn
Status:
Withdrawn
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
To determine the efficacy of iv sildenafil in term and near term infants with PPHN
(persistent pulmonary hypertension of the newborn), by measuring the need for inhaled nitric
oxide (iNO) or extracorporeal membrane oxygenation (ECMO) compared to a historical control
group not treated with sildenafil.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.